脓毒症危重患者中急性呼吸窘迫综合征归因死亡分析
该研究纳入EARLI(n=474)和VALID(n=337)两个前瞻性脓毒症队列,按柏林标准定义ARDS,用logistic回归比较合并与未合并ARDS患者的院内死亡率并控制基线病情严重程度。ARDS在EARLI队列中发生195例(41%),在VALID队列中发生99例(29%)。多因素分析显示ARDS与院内死亡独立相关(EARLI OR 1.65,95%CI 1.02–2.67,p=0.04;VALID OR 2.12,95%CI 1.16–3.92,p=0.02),主要由重度ARDS(P/F<100)驱动;ARDS归因死亡率在EARLI为27%(95%CI 14%–37%),在VALID为37%(95%CI 10%–51%)。ARDS还与ICU死亡、住院时间、ICU时间和无呼吸机天数独立相关。
要点
- 脓毒症ICU患者合并ARDS的归因死亡率在EARLI队列为27%(95%CI 14%–37%),在VALID队列为37%(95%CI 10%–51%)。
- 控制APACHE II评分后,ARDS与院内死亡独立相关:EARLI队列OR 1.65(95%CI 1.02–2.67,p=0.04),VALID队列OR 2.12(95%CI 1.16–3.92,p=0.02)。
- 上述关联主要由重度ARDS(P/F<100)患者驱动。
- ARDS还与ICU死亡、住院时间、ICU时间及无呼吸机天数独立相关。
- 作者认为,针对重度ARDS患者的临床试验最有可能检测到这些结局的可测差异。
适用人群与场景
- 来自EARLI(n=474)和VALID(n=337)两个前瞻性脓毒症队列的ICU患者。
诊断标准与关键阈值
- ARDS按柏林标准定义。
- 重度ARDS定义为P/F<100。
研究设计与关键结果
- 研究类型:基于两个前瞻性脓毒症队列(EARLI n=474;VALID n=337)的分析。
- ARDS发生率:EARLI队列195例(41%),VALID队列99例(29%)。
- 院内死亡主要终点:多因素分析控制APACHE II评分后,ARDS与院内死亡独立相关,EARLI队列OR 1.65(95%CI 1.02–2.67,p=0.04),VALID队列OR 2.12(95%CI 1.16–3.92,p=0.02)。
- 归因死亡率:EARLI队列27%(95%CI 14%–37%),VALID队列37%(95%CI 10%–51%)。
- 关键次要终点:ARDS与ICU死亡、住院时间、ICU时间及无呼吸机天数独立相关。
- 重度ARDS(P/F<100)患者主要驱动上述关联。
证据类型、等级与局限
- 证据类型:基于两个前瞻性队列的分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,针对重度ARDS患者的临床试验最有可能检测到这些结局的可测差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Previous studies assessing impact of acute respiratory distress syndrome (ARDS) on mortality have shown conflicting results. We sought to assess the independent association of ARDS with in-hospital mortality among intensive care unit (ICU) patients with sepsis.
METHODS: We studied two prospective sepsis cohorts drawn from the Early Assessment of Renal and Lung Injury (EARLI; n = 474) and Validating Acute Lung Injury markers for Diagnosis (VALID; n = 337) cohorts. ARDS was defined by Berlin criteria. We used logistic regression to compare in-hospital mortality in patients with and without ARDS, controlling for baseline severity of illness. We also estimated attributable mortality, adjusted for illness severity by stratification.
RESULTS: ARDS occurred in 195 EARLI patients (41%) and 99 VALID patients (29%). ARDS was independently associated with risk of hospital death in multivariate analysis, even after controlling for severity of illness, as measured by APACHE II (odds ratio [OR] 1.65 (95% confidence interval [CI] 1.02, 2.67), p = 0.04 in EARLI; OR 2.12 (CI 1.16, 3.92), p = 0.02 in VALID). Patients with severe ARDS (P/F < 100) primarily drove this relationship. The attributable mortality of ARDS was 27% (CI 14%, 37%) in EARLI and 37% (CI 10%, 51%) in VALID. ARDS was independently associated with ICU mortality, hospital length of stay (LOS), ICU LOS, and ventilator-free days.
CONCLUSIONS: Development of ARDS among ICU patients with sepsis confers increased risk of ICU and in-hospital mortality in addition to other important outcomes. Clinical trials targeting patients with severe ARDS will be best poised to detect measurable differences in these outcomes.
参考来源
- Auriemma CL, Zhuo H, Delucchi K, et al. Acute respiratory distress syndrome-attributable mortality in critically ill patients with sepsis. Intensive Care Med. 2020. PMID: 32206845. doi:10.1007/s00134-020-06010-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。